Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Carmat Expands Its PIVOTAL Study Internationally, In Line With Its Clinical Strategy And CE Marking Process October 5, 2017 Forward Pharma CFO and Two VPs Step Down, Will Cut More Jobs Bringing the Number of Full-Time Employees to Seven April 30, 2017 What a Day! Genentech Lands FDA Approval for First Drug to Treat Severe Multiple Sclerosis March 28, 2017
Carmat Expands Its PIVOTAL Study Internationally, In Line With Its Clinical Strategy And CE Marking Process October 5, 2017
Forward Pharma CFO and Two VPs Step Down, Will Cut More Jobs Bringing the Number of Full-Time Employees to Seven April 30, 2017
What a Day! Genentech Lands FDA Approval for First Drug to Treat Severe Multiple Sclerosis March 28, 2017
